When in doubt, start a fresh vial
Based on Phase 2 data, yes, retatrutide produces more weight loss
The primary comparators of interest were all licensed doses of injectable GLP-1 RAs approved for the treatment of T2Donce-weekly dulaglutide, twice-daily exenatide, once-weekly exenatide extended-release, once-daily liraglutide, once-daily lixisenatide, and once-weekly injectable semaglutide
Clinical Pharmacokinetics, 42(11), 941967
Unlike conventional MR contrast agents, BRNPs release internal Mn 2+ in response to ROS stimulation, which allows for better display of ROS in the tumor and tumor microenvironment, thereby inducing T1-weighted MRI signal enhancement
G., Canale, R